Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | CPT2 | P23786 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | LDHA | P00338 | 1/20 | 0.32 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8656249 | 0.82 | TSHR (0.59) | HMGCRCHRM1TBXA2RADRA1AKDM4E | |
| SCHEMBL11206592 | 0.82 | HMGCR (0.48) | HMGCRCHRM1TBXA2RADRA1AKDM4E | |
| SCHEMBL9736050 | 0.80 | GAA (0.40) | TSHRDGAT1TDP1KCNN4ALDH1A1 | |
| SCHEMBL667169 | 0.80 | TSHR (0.43) | KDM4ETSHRDGAT1KCNN4ALDH1A1 | |
| Hydrochloric Acid SCHEMBL9429165 | 0.79 | NAALAD2 (0.44) | KDM4ETSHRHIF1ADGAT1FFAR1 | |
| SCHEMBL11456464 | 0.78 | HMGCR (0.44) | HMGCRCHRM1TBXA2RADRA1AKDM4E | |
| SCHEMBL18982846 | 0.78 | DGAT1 (0.38) | KDM4ETSHRCYP2C19DGAT1TDP1 | |
| SCHEMBL1544749 | 0.78 | HMGCR (0.44) | HMGCRCHRM1TBXA2RADRA1AKDM4E | |
| SCHEMBL7131099 | 0.78 | KDM4E (0.48) | HMGCRCHRM1TBXA2RADRA1AKDM4E | |
| SCHEMBL4628164 | 0.78 | HMGCR (0.50) | HMGCRCHRM1TBXA2RADRA1AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6415614-B1 | CONTROLLING VAPOR PRESSURE OF MIXTURE | VISTEON GLOBAL TECHNOLOGIES, INC. | 2002-07-09 | — | — | US | claimed |
| EP-0674233-B1 | Recording sheets | XEROX CORP (US) | 2000-05-24 | — | — | EP | claimed |
| US-5928765-A | Recording sheets | XEROX CORPORATION (US) | 1999-07-27 | — | — | US | claimed |
| EP-0674233-A2 | Recording sheets | XEROX CORPORATION (US) | 1995-09-27 | — | — | EP | claimed |
| US-20250281424-A1 | SMALL MOLECULE ANTAGONISTS OF PF4 | ZHOU YUHANG (US) | 2025-09-11 | — | — | US | disclosed |
| US-20250230180-A1 | LPXC INHIBITORS AND USES THEREOF | BLACKSMITH MEDICINES, INC. | 2025-07-17 | — | — | US | disclosed |
| US-20250067907-A1 | COMPOUNDS AND METHODS FOR TREATING HYPERKALEMIA | ARDELYX, INC. (US) | 2025-02-27 | — | — | US | disclosed |
| US-12187754-B2 | LpxC inhibitors and uses thereof | BLACKSMITH MEDICINES, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20240270773-A1 | LPXC INHIBITORS AND USES THEREOF | BLACKSMITH MEDICINES, INC. | 2024-08-15 | — | — | US | disclosed |
| EP-4408853-A1 | LPXC INHIBITORS AND USES THEREOF | Blacksmith Medicines, Inc. (US) | 2024-08-07 | — | — | EP | disclosed |
| EP-4397366-A2 | GLYCYRRHETINIC ACID DERIVATIVES FOR TREATING HYPERKALEMIA | Ardelyx, Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| CN-118302429-A | LPXC inhibitors and uses thereof | 布莱克史密斯医药公司 | 2024-07-05 | — | — | CN | disclosed |
| EP-0317353-A2 | Use of oil soluble dispersant additives in oleaginous compositions | EXXON CHEMICAL PATENTS INC. (US) | 1989-05-24 | — | — | EP | disclosed |
| US-4826815-A | HYPOTENSIVE | ABBOTT LABORATORIES (US) | 1989-05-02 | — | — | US | disclosed |
| EP-0295294-A1 | PEPTIDYLAMINODIOLS | ABBOTT LABORATORIES (US) | 1988-12-21 | — | — | EP | disclosed |
| WO-1988005050-A1 | PEPTIDYLAMINODIOLS | ABBOTT LABORATORIES (US) | 1988-07-14 | — | — | WO | disclosed |
| EP-0258289-A1 | PEPTIDE ANALOGS | ABBOTT LABORATORIES (US) | 1988-03-09 | — | — | EP | disclosed |
| WO-1987004349-A1 | PEPTIDE ANALOGS | DELLARIA JOSEPH | 1987-07-30 | — | — | WO | disclosed |
| EP-0230266-A2 | Functionalized peptidyl aminodiols and -triols | ABBOTT LABORATORIES (US) | 1987-07-29 | — | — | EP | disclosed |
| EP-0229667-A2 | Peptidylaminodiols | ABBOTT LABORATORIES (US) | 1987-07-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250281424-A1 | SMALL MOLECULE ANTAGONISTS OF PF4 | PF4, F12, F2 | HMGCR 2038/4885CHRM1 1357/4885TBXA2R 75/4885 |
| US-20250067907-A1 | COMPOUNDS AND METHODS FOR TREATING HYPERKALEMIA | REN, NHERF1, KCNJ11 | HMGCR 279/4885CHRM1 536/4885TBXA2R 546/4885 |
| US-12187754-B2 | LpxC inhibitors and uses thereof | LPXN, LCT, BPHL | HMGCR 2941/4885CHRM1 4885/4885TBXA2R 3947/4885 |
| US-20250230180-A1 | LPXC INHIBITORS AND USES THEREOF | LPXN, LCT, BPHL | HMGCR 2941/4885CHRM1 4885/4885TBXA2R 3947/4885 |
| US-20240270773-A1 | LPXC INHIBITORS AND USES THEREOF | LPXN, LCT, BPHL | HMGCR 2941/4885CHRM1 4885/4885TBXA2R 3947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.